TGN: Florida Institute finalizes funding agreement with TransGenex Nanobiotech
The Florida Institute for the Commercialization of Public Research (the Institute) has finalized a funding agreement with TransGenex Nanobiotech, Inc. (TGN), a company that is developing nano─scale technologies for novel, cost─effective diagnostic and therapeutic agents against cancers and other inflammatory diseases.
Read full article »
Co-Founder
Shyam Mohapatra
TGN is a provider of drug-resistant tumor catalyzing and customized cancer tests.
Read more